Description
OVERVIEW
Originally developed for type 2 diabetes management, Tirzepatide has demonstrated additional benefits, including cardiovascular protection and effective weight loss support. This synthetic peptide is derived from gastric inhibitory polypeptide (GIP) while also acting as a glucagon-like peptide-1 (GLP-1) receptor agonist, allowing it to:
- Regulate blood sugar levels
- Enhance insulin sensitivity
- Promote satiety
- Facilitate weight loss
RESEARCH
Tirzepatide is a synthetic analogue of gastric inhibitory polypeptide (GIP), designed to stimulate insulin release and support the management of type 2 diabetes and non-alcoholic fatty liver disease. Composed of 39 amino acids, this peptide functions by activating both GIP and GLP-1 receptors, leading to improved insulin regulation and metabolic balance.
Long-term use of Tirzepatide has been shown to increase adiponectin levels by up to 26%, contributing to:
- Reduced hunger and cravings
- Lower fasting insulin levels
- Greater insulin sensitivity
These metabolic effects result in:
- Significant weight loss (approximately 11 kg or 25 lbs)
- Enhanced glucose control
- Decreased fat storage
- Lower cardiovascular risk factors
STRUCTURE
- Amino Acid Sequence: YE-Aib-GTFTSDYSI-Aib-LDKIAQ AFVQWLIAGGPSSGAPPPS
(Aib is a non-standard amino acid: H H-C(CH3)COOH)- Molecular Formula: C₂₂₅H₃₄₈N₄₈O₆₈
- Molecular Weight: 4813.527 g/mol
- PubChem Identifier: 156588324
- CAS Registry Number: 2023788-19-2
- Alternative Names: P1206, LY3298176
CITATIONS
Source: PubChem
Reviews
There are no reviews yet.